Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-03-24
Target enrollment:
Participant gender:
Summary
This phase II trial investigates the effect of venetoclax and eprenetapopt in treating
patients with mantle cell lymphoma that has come back (relapsed) or dose not respond to
treatment (refractory). Chemotherapy drugs, such as venetoclax and eprenetapopt, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading.